CD300LD Knockout HT29 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population designed to disrupt the CD300LD gene in HT29 colorectal adenocarcinoma cells. This loss-of-function model enables rigorous investigation of CD300LD, an ITIM-containing inhibitory receptor, without clonal selection artifacts. The heterogeneous pool facilitates robust phenotypic analysis, making it suitable for studying CD300LD??s role in immune regulation and tumor biology.
The HT29 cell line, derived from a human colorectal adenocarcinoma, features an epithelial morphology and is widely used in cancer research, including intestinal epithelial studies and drug screening. Its well-characterized background supports gene-editing applications, and when combined with CD300LD knockout, it offers a platform to examine immune checkpoint pathways in a tumor-relevant epithelial context, potentially informing on tumor-immune interactions.
CD300LD modulates immune responses through its cytoplasmic ITIMs. Upon ligand engagement (e.g., phosphatidylserine), it recruits phosphatases SHP-1 and SHP-2, which dephosphorylate Syk kinase downstream of ITAM-coupled receptors. This attenuates NF-??B signaling and suppresses effector functions such as cytokine release. The knockout removes this inhibitory control, allowing dissection of signaling networks dependent on SHP-1/SHP-2 recruitment and downstream targets.
In HT29 cells, CD300LD disruption serves as a model for inhibitory receptor function in a colorectal cancer background. Although typically myeloid-restricted, aberrant CD300LD expression may occur in epithelial tumors, influencing immune evasion. This model facilitates exploration of CD300LD??s impact on tumor cell signaling and immune cell crosstalk in co-culture systems, advancing understanding of immune checkpoint regulation in cancer.
Applications include flow cytometry for surface marker analysis, Western blotting for ITIM pathway components, and co-culture assays with immune cells to evaluate functional checkpoint modulation. Cytokine secretion profiling can reveal alterations in tumor-immune communication. These assays support research in autoimmunity, cancer immunotherapy, and myeloid signaling. For further information or to order, please contact Ascent Research.
